Physiomics and Bicycle Therapeutics to present on preclinical modelling of an immune therapy at SITC 2021 Annual Meeting
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it is presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting taking place at the Walter E. Washington Convention Center, Washington, USA from 10-14 November 2021.
The Company and its client Bicycle Therapeutics will today be presenting an original poster (abstract #826) in an ePoster format. The poster is titled “Establishing the preclinical/translational PK/PD relationship for BT7480, a Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)”.
The Company’s modelling determined that the level of tumour infiltrating CD8+ T-cells fully captures the treatment effect of BT7480 on tumour growth in an in vivo preclinical model. A PK/PD modelling framework was developed that predicts preclinical biomarker level and tumour growth inhibition in response to changes in the BT7480 dose and dosing schedule.
More information about the conference can be found using the following link: https://www.sitcancer.org/2021/home.
The poster is now available on the Physiomics website at this link: https://www.physiomics.co.uk/resources/.
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.